secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108426
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo reports Q2 net loss $26.1M, advances LX2006 with Breakthrough Therapy, appoints new CFO
--------------------------------------------------------------------------------

- Net loss $26.1M ($0.60/sh) vs $21.2M ($0.64/sh) in Q2 2024; cash $152.5M expected to fund operations into 2028.
- LX2006 granted FDA Breakthrough Therapy designation based on interim data; registrational study expected early 2026.
- Eight participants dosed in Phase I/II HEROIC-PKP2 trial of LX2020; interim data update expected H2 2025.
- Closed $80M equity financing in May 2025; strategic partnership for non-viral RNA cardiac therapies.
- Louis Tamayo appointed CFO effective Aug 15, 2025, succeeding Kyle Rasbach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/0000950170-25-108426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/lxeo-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer